<DOC>
	<DOC>NCT02171442</DOC>
	<brief_summary>The aim of this study were to investigate the metabolism and pharmacokinetics of BIBR 1048 MS and BIBR 953 ZW in man.</brief_summary>
	<brief_title>Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Healthy male subjects as determined by results of screening Signed written informed consent from each subject in accordance with the regulatory and legal requirements of the UK Age between 30 and 55 years of age Body Mass Index (BMI) of between 18.5 and 29.9 kg/m² Any of the findings from the medical examination (including BP, pulse rate and ECG) deviated from normal or were of clinical relevance History of current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders History of relevant orthostatic hypotension, fainting spells and blackouts, or volunteers with diseases of the central nervous system (such as epilepsy) or psychiatric disorders Diseases of the central nervous system (such as epilepsy) or psychiatric disorders Chronic or relevant acute infections History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the principal investigator History of any bleeding disorder including prolonged or habitual bleeding History of other hematologic disease History of cerebral bleeding (e.g. after a car accident) History of craniocerebral trauma Intake of drugs with a long half life (≥ 24h) within 1 month prior to administration Any drugs which may have had an influence on the results of the trial within 10 days prior to administration or during the trial Any volunteers who had participated in another trial with an investigational drug within 3 months ( 4 months if the drug was a new chemical entity) prior to administration or during the trial Exposition to radiation in the previous 12 months (i.e. serial xrays, CT scan or barium meal) Smoker Alcohol abuse (&gt; 60 g/day) Drug abuse Blood donation within 12 weeks prior to administration or during the trial Any excessive physical activities within 5 days prior to administration or during the trial Any laboratory value outside the clinically accepted reference range History of familial bleeding disorder Platelets &gt; 150 x 109 /l Unable to defecate at least once a day every two days</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>